loading
Precedente Chiudi:
$38.61
Aprire:
$38.05
Volume 24 ore:
3.09M
Relative Volume:
0.90
Capitalizzazione di mercato:
$3.70B
Reddito:
$2.23B
Utile/perdita netta:
$-248.39M
Rapporto P/E:
-13.98
EPS:
-2.69
Flusso di cassa netto:
$-697.55M
1 W Prestazione:
-0.79%
1M Prestazione:
-38.21%
6M Prestazione:
-71.80%
1 anno Prestazione:
-69.79%
Intervallo 1D:
Value
$36.96
$38.15
Intervallo di 1 settimana:
Value
$36.89
$39.55
Portata 52W:
Value
$34.10
$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Nome
Sarepta Therapeutics Inc
Name
Telefono
617-274-4000
Name
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Name
Dipendente
1,372
Name
Cinguettio
@sarepta
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
SRPT's Discussions on Twitter

Confronta SRPT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
37.60 3.72B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-08 Downgrade Evercore ISI Outperform → In-line
2025-04-11 Iniziato Wells Fargo Overweight
2025-04-02 Aggiornamento H.C. Wainwright Sell → Neutral
2025-03-31 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-02-11 Iniziato Deutsche Bank Hold
2024-11-27 Reiterato Needham Buy
2024-11-25 Iniziato H.C. Wainwright Sell
2024-11-07 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-10-21 Iniziato Jefferies Buy
2024-10-10 Ripresa Raymond James Outperform
2024-07-29 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2024-06-26 Downgrade Citigroup Buy → Neutral
2024-05-31 Iniziato Piper Sandler Overweight
2024-05-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-05-14 Aggiornamento Oppenheimer Perform → Outperform
2024-01-31 Iniziato BMO Capital Markets Outperform
2023-12-13 Ripresa Citigroup Buy
2023-12-12 Iniziato Deutsche Bank Buy
2023-11-21 Iniziato Wedbush Outperform
2023-10-31 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-10-31 Downgrade Oppenheimer Outperform → Perform
2023-06-23 Downgrade Evercore ISI Outperform → In-line
2023-04-26 Iniziato SMBC Nikko Outperform
2023-04-04 Iniziato Citigroup Buy
2023-03-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-12-22 Reiterato BTIG Research Buy
2022-12-16 Aggiornamento UBS Neutral → Buy
2022-04-04 Ripresa Cantor Fitzgerald Overweight
2022-01-05 Reiterato Needham Buy
2021-12-09 Aggiornamento Oppenheimer Perform → Outperform
2021-11-05 Aggiornamento JP Morgan Neutral → Overweight
2021-09-15 Aggiornamento Guggenheim Neutral → Buy
2021-08-05 Aggiornamento JP Morgan Underweight → Neutral
2021-06-15 Iniziato BTIG Research Buy
2021-04-26 Ripresa Credit Suisse Neutral
2021-01-12 Downgrade Citigroup Buy → Neutral
2021-01-11 Downgrade UBS Buy → Neutral
2021-01-08 Downgrade JP Morgan Overweight → Underweight
2021-01-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-01-08 Downgrade Raymond James Outperform → Mkt Perform
2020-11-11 Iniziato Berenberg Hold
2020-10-28 Iniziato UBS Buy
2020-08-25 Iniziato Raymond James Outperform
2020-08-20 Downgrade Credit Suisse Outperform → Neutral
2020-03-31 Iniziato Mizuho Buy
2019-11-01 Iniziato Guggenheim Buy
2019-08-21 Reiterato Needham Buy
2019-07-09 Reiterato Morgan Stanley Overweight
2019-07-01 Reiterato RBC Capital Mkts Outperform
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-11 Reiterato Credit Suisse Outperform
2018-10-12 Iniziato Bernstein Outperform
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-09-26 Reiterato RBC Capital Mkts Outperform
2018-09-14 Ripresa BofA/Merrill Buy
2018-09-06 Iniziato Credit Suisse Outperform
2018-08-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-06-21 Reiterato Robert W. Baird Outperform
2018-06-20 Reiterato Needham Buy
2018-06-19 Reiterato H.C. Wainwright Buy
Mostra tutto

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

pulisher
May 29, 2025

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com

May 29, 2025
pulisher
May 29, 2025

July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

May 29, 2025
pulisher
May 29, 2025

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

May 29, 2025
pulisher
May 27, 2025

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About These 11 Stocks? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com

May 27, 2025
pulisher
May 26, 2025

Will Moderna's Rally Continue? - Forbes

May 26, 2025
pulisher
May 22, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent

May 22, 2025
pulisher
May 22, 2025

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive

May 22, 2025
pulisher
May 22, 2025

SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch

May 21, 2025
pulisher
May 21, 2025

Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance

May 19, 2025
pulisher
May 17, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire

May 16, 2025
pulisher
May 15, 2025

Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com

May 15, 2025
pulisher
May 15, 2025

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com

May 14, 2025
pulisher
May 14, 2025

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns - TipRanks

May 14, 2025

Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):